The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients

Background Pulmonary arterial hypertension (PAH) is a rare condition that can ultimately lead to right heart failure and death. In this study we estimated the health care costs and resource utilization associated with PAH in a large US managed care health plan.